TACSTD2 and metastatic malignant neoplasm in the lymph nodes: Interestingly, worrisome clinicopathological features, such as poor histological grade (well or moderate: 38.8% vs. poor: 86.3%, p = 0.000), aggressive tumor invasion (T1–T2: 44.4% vs. T3–T4: 80.4%, p = 0.000), lymph node metastasis (N0: 43.1% vs. N1–2:85.1%, p = 0.001) and higher TNM stage (I–II: 23.7% vs. III–IV: 83.6%, p = 0.000) were strongly associated with high TROP-2 expression [23].